Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

SAN DIEGO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2009. The Company reported total revenue of $211.2 million for the third quarter, including net product sales of $192.9 million. Non-GAAP operating income was $0.6 million for the quarter ended September 30, 2009 compared to non-GAAP operating loss of $32.7 million for the same period in 2008. Net loss for the quarter ended September 30, 2009 was $26.7 million, or $0.19 per share compared to $79.0 million, or $0.58 per share for the same period in 2008. Net loss for the quarter ended September 30, 2008 included a loss on impairment of investments of $14.9 million, or $0.11 per share. At September 30, 2009 the Company held cash, cash equivalents and short-term investments of $619.7 million.

"We continue to make substantial progress toward our goal of becoming operating cash flow positive on a sustainable basis by the end of 2010, and have generated positive cash flow in the third quarter," said Mark G. Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals. "Over the next few quarters we will make incremental investments to successfully launch exenatide once weekly, which will lead to variability in our operating results, but we expect to achieve sustainable positive operating cash flow by the end of next year."

Quarter Ended September 30, 2009

Net product sales of $192.9 million for the quarter ended September 30, 2009 include $171.1 million for BYETTA® (exenatide) injection and $21.8 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $201.4 million consisting of $179.9 million for BYETTA and $21.5 million for SYMLIN for the same period in 2008. Revenues
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans ... OxyContin is a serious public health and safety issue in ... from a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication ... progress with this very serious health situation facing our country," ...
(Date:8/21/2014)... August 21, 2014 BreedIT ... Ltd., the exclusive worldwide license holder and distributor ... breeders and researchers, today is pleased to announce ... with Seach Ltd, a leading Israeli medical Cannabis ... and develop new breeds of medical Cannabis to ...
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2
... Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical,company Pharmaxis (ASX: PXS; ... positive,results of its recently completed international Phase III trial ... represents one of,the largest clinical trials conducted in cystic ... of the trial was to assess whether Bronchitol,improves lung ...
... Va., May 1 C. Larry Pope, President and ... SFD ), sent the following update to all ... at its joint venture operation in Veracruz:To Our Employees:The ... on a minute-to-minute basis, and while we would like ...
Cached Medicine Technology:Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 2Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 4Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 5Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Cardiomyopathy ... the function of the myocardium (the heart muscle) ... common symptoms are dyspnea (breathlessness) and peripheral edema ... often at risk of dangerous forms of irregular ... common form of cardiomyopathy is dilated cardiomyopathy. , ...
(Date:8/23/2014)... 2014 Peripheral intervention surgeries are part ... etc, thereby addressing the root cause of peripheral artery ... to the other part of the arteries where the ... procedures require the use of a catheter, (which is ... these catheters are inserted through a thin cut in ...
(Date:8/23/2014)... New York (PRWEB) August 23, 2014 ... ) filed on behalf of individuals who ... Conserve hip replacement line continue to move forward ... Georgia, Bernstein Liebhard LLP reports. According to an ... a bellwether trial program that would allow the ...
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... Teen drug and alcohol abuse is a major ... NC. Substance abuse can happen to people of all ... alcohol dependency in higher numbers than ever before. ... but don’t know where to find professional youth rehab. ... challenge because most treatment options are designed for adults. ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... recently diagnosed with diabetes and hypertension have time to ... pressure without medications, but not too much time. ... up to a year were smalla two-day reduction in ... Chicago researchers published online for the Journal of ...
... the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial ... control group of men undergoing usual care, according to a ... the National Cancer Institute. The Prostate, ... multi-center, two-arm trial, which began enrollment in November 1993 with ...
... of imaging services received by patients in a hospital, in-patient ... the Journal of the American College of Radiology . ... of the population, were without health insurance for some or ... preventive care, delays in diagnosis and unnecessary deaths. ...
... FRIDAY, Jan. 6 (HealthDay News) -- Air pollution may increase ... in black American women, a new study suggests. Previous ... acute cardiovascular events such as stroke and heart attack, but ... of chronic diseases such as diabetes and high blood pressure ...
... , FRIDAY, Jan. 6 (HealthDay News) -- If the current ... has left you searching for something else for your child ... the effects of these medications can vary widely. ... much of the drug is absorbed into the bloodstream], and ...
... documents shows that Philip Morris USA manipulated data on ... actual toxicity levels and increasing the risk of heart, ... information can,t be taken at face value, the researchers ... of additives, including menthol, should be eliminated from cigarettes ...
Cached Medicine News:Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 2Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 3Health News:Study shows no evidence of a mortality benefit to PSA screening 2Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 3Health News:Tobacco company misrepresented danger from cigarettes 2
... cost-effective line of compact CO2 systems available ... 30 or 40 watts combines portability ... extremely accurate laser beam, as well as ... advantageous for small operating theatres and are ...
... Applications include PhotoLightFACIAL facial skin ... vein removal. Incorporates a ... to 1200nm), multiple hand pieces ... give you the most flexibility. ...
... delivered through an ultra thin flexible 400 - ... freedom of movement when performing surgery. The ... range of handpieces. Handpieces are supplied with ... mm. Straight and angled fiber guides with ...
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
Medicine Products: